Indeed, GLP-1 receptor agonists are transforming the management of type 2 diabetes and obesity globally. Nevertheless, recent clinical concerns have emerged regarding a possible link between these medications and nonarteritic anterior ischemic optic neuropathy (NAION). This potentially vision-threatening condition causes sudden, painless vision loss. Consequently, a new nationwide cohort study from Sweden investigated this risk to provide clarity for clinicians.
Evaluating NAION Risk with GLP-1 Receptor Agonists
Specifically, the researchers conducted a register-based cohort study using Swedish national registry data from 2013 to 2024. They compared patients initiating GLP-1RAs with those initiating sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Furthermore, the investigators utilized propensity score weighting to adjust for baseline differences between the groups. This design successfully emulated a target clinical trial.
Key Findings and Clinical Interpretations
Ultimately, the study included 107,518 users of GLP-1RAs and 185,898 users of SGLT-2 inhibitors. During follow-up, 62 GLP-1RA users and 64 SGLT-2 inhibitor users developed anterior ischemic optic neuropathy. Therefore, the absolute risk of developing this condition remained extremely low for both groups. In contrast, the GLP-1RA group had a higher relative risk. Specifically, they showed a risk ratio of 1.93 at one year and 1.69 at five years. However, this apparent risk difference decreased substantially when researchers restricted the analysis to patients taking metformin at baseline. Specifically, the risk ratio dropped to 1.40 at one year and 1.23 at five years, showing no statistically significant difference.
What This Means for Clinicians in India
For physicians in India, these findings offer reassuring clinical guidance. Consequently, the risk difference disappeared after adjusting for baseline metformin use. This shift indicates that residual confounding likely explains the association. Therefore, the study suggests that the drugs themselves are highly unlikely to cause NAION. Additionally, because absolute risks are extremely small, clinicians can prescribe these therapies with confidence when clinically indicated. Instead, they should maintain standard ophthalmological vigilance in high-risk diabetic patients.
Frequently Asked Questions
Q1: Does this study show that GLP-1 receptor agonists directly cause NAION?
No, the study does not establish a causal link. Specifically, the initial relative risk difference disappeared after adjusting for baseline metformin use. Therefore, the observed association is likely due to residual confounding by diabetes severity rather than a direct drug effect.
Q2: Should clinicians in India stop prescribing GLP-1 receptor agonists due to eye safety concerns?
No, clinicians do not need to alter their prescribing habits. Indeed, the absolute risk of developing this optic neuropathy remains extremely low for most patients. Consequently, the clinical benefits of these medications for diabetes and weight control continue to outweigh the rare potential risks.
Q3: What was the primary comparator drug class used in this register-based cohort study?
Specifically, researchers compared GLP-1 receptor agonists with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. They chose this comparison because both classes serve as common second-line or third-line treatments for type 2 diabetes. Furthermore, SGLT-2 inhibitors have no known association with optic neuropathy, making them an ideal comparator.
References
- Ueda P et al. Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study. Ann Intern Med. 2026 Jul 14. doi: 10.7326/ANNALS-25-02096. PMID: 42441962.
- Reynolds KR et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy: A Target Trial Emulation. Ann Intern Med. 2026 Jul 14. doi: 10.7326/ANNALS-25-01050.
- North American Neuro-Ophthalmology Society (NANOS) and the American Academy of Ophthalmology. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement. May 2026.